

Philip J Mease

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5563729/publications.pdf>

Version: 2024-02-01

268
papers

31,604
citations

13099

68
h-index

4548

171
g-index

279
all docs

279
docs citations

279
times ranked

17972
citing authors

#	ARTICLE	IF	CITATIONS
1	2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Arthritis and Rheumatism</i> , 2010, 62, 2569-2581.	6.7	6,781
2	Classification criteria for psoriatic arthritis: Development of new criteria from a large international study. <i>Arthritis and Rheumatism</i> , 2006, 54, 2665-2673.	6.7	2,811
3	Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. <i>Lancet</i> , The, 2000, 356, 385-390.	13.7	1,387
4	2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 319-329.	3.4	1,173
5	Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double-blind, randomized, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2005, 52, 3279-3289.	6.7	828
6	Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression. <i>Arthritis and Rheumatism</i> , 2004, 50, 2264-2272.	6.7	823
7	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 1060-1071.	5.6	726
8	Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet</i> , The, 2015, 386, 1137-1146.	13.7	722
9	Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. <i>New England Journal of Medicine</i> , 2015, 373, 1329-1339.	27.0	629
10	Golimumab, a new human tumor necrosis factor β antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. <i>Arthritis and Rheumatism</i> , 2009, 60, 976-986.	6.7	547
11	Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 3-17.	0.9	484
12	Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naïve patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 79-87.	0.9	454
13	Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 815-822.	0.9	449
14	Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis. <i>New England Journal of Medicine</i> , 2017, 377, 1537-1550.	27.0	434
15	Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. <i>Journal of the American Academy of Dermatology</i> , 2013, 69, 729-735.	1.2	397
16	Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1020-1026.	0.9	372
17	Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: A multinational, double-blind, randomized, placebo-controlled clinical trial. <i>Arthritis and Rheumatism</i> , 2004, 50, 1939-1950.	6.7	366
18	Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis. <i>New England Journal of Medicine</i> , 2014, 370, 2295-2306.	27.0	350

#	ARTICLE	IF	CITATIONS
19	Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. <i>Lancet, The</i> , 2017, 389, 2317-2327.	13.7	316
20	2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2019, 71, 5-32.	5.6	312
21	Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthri. <i>Arthritis Care and Research</i> , 2011, 63, S64-85.	3.4	277
22	Abatacept in the treatment of patients with psoriatic arthritis: Results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. <i>Arthritis and Rheumatism</i> , 2011, 63, 939-948.	6.7	264
23	2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2019, 71, 2-29.	3.4	264
24	Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. <i>Lancet, The</i> , 2018, 392, 2441-2451.	13.7	251
25	The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 986-991.	0.9	240
26	Fibromyalgia Syndrome Module at OMERACT 9: Domain Construct. <i>Journal of Rheumatology</i> , 2009, 36, 2318-2329.	2.0	209
27	Managing Patients with Psoriatic Disease: The Diagnosis and Pharmacologic Treatment of Psoriatic Arthritis in Patients with Psoriasis. <i>Drugs</i> , 2014, 74, 423-441.	10.9	209
28	A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 123-131.	0.9	206
29	Guselkumab in biologic-naïve patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2020, 395, 1126-1136.	13.7	206
30	International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 673-680.	0.9	194
31	Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrhumdis-2017-212687.	0.9	193
32	Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1550-1558.	0.9	184
33	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. <i>Nature Reviews Rheumatology</i> , 2022, 18, 465-479.	8.0	182
34	Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. <i>Lancet, The</i> , 2020, 395, 1496-1505.	13.7	178
35	Colimumab in psoriatic arthritis: One-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2012, 64, 2504-2517.	6.7	171
36	Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial. <i>Arthritis and Rheumatology</i> , 2019, 71, 1112-1124.	5.6	164

#	ARTICLE	IF	CITATIONS
37	Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial. <i>Lancet</i> , The, 2018, 392, 2367-2377.	13.7	159
38	Consensus on a core set of domains for psoriatic arthritis. <i>Journal of Rheumatology</i> , 2007, 34, 1167-70.	2.0	155
39	Assessment of physical function and participation in chronic pain clinical trials: IMMPACT/OMERACT recommendations. <i>Pain</i> , 2016, 157, 1836-1850.	4.2	152
40	Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis. <i>Current Opinion in Rheumatology</i> , 2015, 27, 127-133.	4.3	151
41	Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. <i>Journal of Rheumatology</i> , 2006, 33, 712-21.	2.0	145
42	Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. <i>Lancet</i> , The, 2020, 395, 53-64.	13.7	138
43	Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. <i>Journal of Rheumatology</i> , 2007, 34, 1040-50.	2.0	135
44	The Efficacy and Safety of Clazakizumab, an Anti-Interleukin-6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 2163-2173.	5.6	134
45	Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1400-1413.	0.9	132
46	Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 312-320.	0.9	131
47	Longterm (52-week) Results of a Phase III Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2015, 42, 479-488.	2.0	122
48	Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study. <i>Rheumatology</i> , 2017, 56, 1993-2003.	1.9	121
49	Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3). <i>Arthritis Research and Therapy</i> , 2018, 20, 47.	3.5	117
50	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012: Table A1. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, ii2-ii34.	0.9	114
51	Psoriatic arthritis. <i>Nature Reviews Disease Primers</i> , 2021, 7, 59.	30.5	113
52	Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study). <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1689-1694.	0.9	112
53	International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis. <i>Arthritis and Rheumatism</i> , 2009, 61, 1235-1242.	6.7	104
54	Patient Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA and OMERACT Study. <i>Journal of Rheumatology</i> , 2011, 38, 898-903.	2.0	101

#	ARTICLE	IF	CITATIONS
55	Influence of Axial Involvement on Clinical Characteristics of Psoriatic Arthritis: Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. <i>Journal of Rheumatology</i> , 2018, 45, 1389-1396.	2.0	100
56	Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016. <i>Journal of Rheumatology</i> , 2017, 44, 1522-1528.	2.0	93
57	Fibromyalgia, a missed comorbidity in spondyloarthritis: prevalence and impact on assessment and treatment. <i>Current Opinion in Rheumatology</i> , 2017, 29, 304-310.	4.3	92
58	Minimally Important Difference of Health Assessment Questionnaire in Psoriatic Arthritis: Relating Thresholds of Improvement in Functional Ability to Patient-rated Importance and Satisfaction. <i>Journal of Rheumatology</i> , 2011, 38, 2461-2465.	2.0	91
59	Clinical Characteristics, Disease Activity, and Patient-reported Outcomes in Psoriatic Arthritis Patients With Dactylitis or Enthesitis: Results From the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. <i>Arthritis Care and Research</i> , 2017, 69, 1692-1699.	3.4	91
60	Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 815-822.	0.9	88
61	Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT. <i>Arthritis Research and Therapy</i> , 2010, 12, R113.	3.5	85
62	Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study. <i>Lancet</i> , 2018, 392, 134-144.	13.7	81
63	Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 185-193.	0.9	79
64	Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 203-207.	0.9	78
65	Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study. <i>Journal of Rheumatology</i> , 2016, 43, 1713-1717.	2.0	77
66	International spondyloarthritis interobserver reliability exercise--the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. <i>Journal of Rheumatology</i> , 2007, 34, 1740-5.	2.0	74
67	Qualifying Unmet Needs and Improving Standards of Care in Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2014, 66, 1759-1766.	3.4	73
68	Clinical characteristics of psoriatic arthritis and psoriasis in dermatologists' offices. <i>Journal of Dermatological Treatment</i> , 2006, 17, 279-287.	2.2	72
69	Secukinumab for Long-term Treatment of Psoriatic Arthritis: A Two-Year Followup From a Phase III, Randomized, Double-blind Placebo-controlled Study. <i>Arthritis Care and Research</i> , 2017, 69, 347-355.	3.4	72
70	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 345-355.	5.6	72
71	Frequency of Axial Spondyloarthritis Diagnosis Among Patients Seen by US Rheumatologists for Evaluation of Chronic Back Pain. <i>Arthritis and Rheumatology</i> , 2016, 68, 1669-1676.	5.6	71
72	Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo-controlled Study. <i>Arthritis Care and Research</i> , 2016, 68, 267-274.	3.4	69

#	ARTICLE	IF	CITATIONS
73	Randomized Controlled Trial of Adalimumab in Patients With Nonpsoriatic Peripheral Spondyloarthritis. <i>Arthritis and Rheumatology</i> , 2015, 67, 914-923.	5.6	67
74	Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 1914-1921.	5.6	64
75	Societal costs and patients' experience of health inequities before and after diagnosis of psoriatic arthritis: a Danish cohort study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1495-1501.	0.9	63
76	Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 88-93.	0.9	63
77	Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the Corrona registry. <i>RMD Open</i> , 2015, 1, e000181.	3.8	62
78	Toward Development of a Fibromyalgia Responder Index and Disease Activity Score: OMERACT Module Update. <i>Journal of Rheumatology</i> , 2011, 38, 1487-1495.	2.0	60
79	Brief Report: Reduced Joint Counts Misclassify Patients With Oligoarticular Psoriatic Arthritis and Miss Significant Numbers of Patients With Active Disease. <i>Arthritis and Rheumatism</i> , 2013, 65, 1504-1509.	6.7	60
80	Application of composite disease activity scores in psoriatic arthritis to the PRESTA data set. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 358-362.	0.9	57
81	International spondyloarthritis interobserver reliability exercise--the INSPIRE study: I. Assessment of spinal measures. <i>Journal of Rheumatology</i> , 2007, 34, 1733-9.	2.0	57
82	Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial. <i>RMD Open</i> , 2018, 4, e000723.	3.8	56
83	Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1310-1319.	0.9	56
84	Validation of the OMERACT Psoriatic Arthritis Magnetic Resonance Imaging Score (PsAMRIS) for the Hand and Foot in a Randomized Placebo-controlled Trial. <i>Journal of Rheumatology</i> , 2015, 42, 2473-2479.	2.0	54
85	Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study. <i>Rheumatology and Therapy</i> , 2020, 7, 553-580.	2.3	54
86	Characterization of Patients With Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis in the <sc>US</sc>-Based Corrona Registry. <i>Arthritis Care and Research</i> , 2018, 70, 1661-1670.	3.4	53
87	Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies. <i>Lancet Rheumatology</i> , The, 2021, 3, e715-e723.	3.9	53
88	Biologic Therapy for Psoriatic Arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2015, 41, 723-738.	1.9	52
89	Real-world burden of comorbidities in US patients with psoriatic arthritis. <i>RMD Open</i> , 2017, 3, e000588.	3.8	52
90	Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 83-88.	0.9	51

#	ARTICLE	IF	CITATIONS
91	Psoriatic arthritis and spondyloarthritis assessment and management update. Current Opinion in Rheumatology, 2013, 25, 287-296.	4.3	51
92	Drug Therapies for Peripheral Joint Disease in Psoriatic Arthritis: A Systematic Review. Journal of Rheumatology, 2014, 41, 2277-2285.	2.0	51
93	A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiative. Seminars in Arthritis and Rheumatism, 2018, 47, 654-665.	3.4	50
94	Revised chronic widespread pain criteria: development from and integration with fibromyalgia criteria. Scandinavian Journal of Pain, 2019, 20, 77-86.	1.3	50
95	Efficacy and Safety of Guselkumab, an Interleukin-23p19-Specific Monoclonal Antibody, Through One Year in Biologic-Naive Patients With Psoriatic Arthritis. Arthritis and Rheumatology, 2021, 73, 604-616.	5.6	48
96	Axial involvement in psoriatic arthritis: An update for rheumatologists. Seminars in Arthritis and Rheumatism, 2021, 51, 880-887.	3.4	48
97	Safety of Ixekizumab in Patients With Psoriatic Arthritis: Results From a Pooled Analysis of Three Clinical Trials. Arthritis Care and Research, 2019, 71, 367-378.	3.4	47
98	Patient-reported Outcomes in a Randomized Trial of Etanercept in Psoriatic Arthritis. Journal of Rheumatology, 2010, 37, 1221-1227.	2.0	46
99	A Comparison of the Malignancy Incidence Among Patients With Psoriatic Arthritis and Patients With Rheumatoid Arthritis in a Large US Cohort. Arthritis and Rheumatology, 2014, 66, 1472-1481.	5.6	46
100	Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond. RMD Open, 2019, 5, e000808.	3.8	46
101	Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs. RMD Open, 2019, 5, e000806.	3.8	44
102	Comparison of Men and Women With Axial Spondyloarthritis in the US-based Corrona Psoriatic Arthritis/Spondyloarthritis Registry. Journal of Rheumatology, 2021, 48, 1528-1536.	2.0	44
103	Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis. Rheumatology, 2021, 60, 2109-2121.	1.9	44
104	PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials. Journal of Rheumatology, 2019, 46, 990-995.	2.0	43
105	Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study. Annals of the Rheumatic Diseases, 2021, 80, 1147-1157.	0.9	43
106	Standardizing Training for Psoriasis Measures. JAMA Dermatology, 2013, 149, 577.	4.1	42
107	Defining Outcome Measures for Psoriatic Arthritis: A Report from the GRAPPA-OMERACT Working Group. Journal of Rheumatology, 2017, 44, 697-700.	2.0	42
108	Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study. Rheumatology and Therapy, 2021, 8, 903-919.	2.3	41

#	ARTICLE	IF	CITATIONS
109	Long-term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through Two Years: Results From a Phase III, Randomized, Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naïve Patients With Active Psoriatic Arthritis. Arthritis and Rheumatology, 2022, 74, 175-185.	5.6	41
110	Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5. Rheumatology, 2020, 59, 1325-1334.	1.9	40
111	Application and Modifications of Minimal Disease Activity Measures for Patients with Psoriatic Arthritis Treated with Adalimumab: Subanalyses of ADEPT. Journal of Rheumatology, 2013, 40, 647-652.	2.0	39
112	Performance of 3 Enthesitis Indices in Patients with Peripheral Spondyloarthritis During Treatment with Adalimumab. Journal of Rheumatology, 2017, 44, 599-608.	2.0	39
113	Minimal Disease Activity Among Active Psoriatic Arthritis Patients Treated With Secukinumab: 2-Year Results From a Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Study. Arthritis Care and Research, 2018, 70, 1529-1535.	3.4	39
114	Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison. Rheumatology and Therapy, 2018, 5, 99-122.	2.3	39
115	Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5-Year Results from the Phase 3 FUTURE 1 Study. ACR Open Rheumatology, 2020, 2, 18-25.	2.1	39
116	Considerations for the definition of remission criteria in psoriatic arthritis. Seminars in Arthritis and Rheumatism, 2018, 47, 786-796.	3.4	38
117	Management of psoriatic arthritis: The therapeutic interface between rheumatology and dermatology. Current Rheumatology Reports, 2006, 8, 348-354.	4.7	37
118	Endorsement of the 66/68 Joint Count for the Measurement of Musculoskeletal Disease Activity: OMERACT 2018 Psoriatic Arthritis Workshop Report. Journal of Rheumatology, 2019, 46, 996-1005.	2.0	36
119	Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018. Annals of the Rheumatic Diseases, 2019, 78, 872-878.	0.9	36
120	Systematic literature review of domains assessed in psoriatic arthritis to inform the update of the psoriatic arthritis core domain set. RMD Open, 2016, 2, e000217.	3.8	35
121	Pain Mechanisms and Ultrasonic Inflammatory Activity as Prognostic Factors in Patients With Psoriatic Arthritis: A Prospective Cohort Study. Arthritis Care and Research, 2019, 71, 798-810.	3.4	35
122	Updating the OMERACT Filter: Implications of Filter 2.0 to Select Outcome Instruments Through Assessment of ‘‘Truth’’: Content, Face, and Construct Validity. Journal of Rheumatology, 2014, 41, 1000-1004.	2.0	34
123	Enhanced Patient Involvement and the Need to Revise the Core Set ‘‘Report from the Psoriatic Arthritis Working Group at OMERACT 2014. Journal of Rheumatology, 2015, 42, 2198-2203.	2.0	34
124	Managing Comorbid Disease in Patients with Psoriatic Arthritis. Current Rheumatology Reports, 2010, 12, 281-287.	4.7	31
125	Comparative Analysis of Disease Activity Measures, Use of Biologic Agents, Body Mass Index, Radiographic Features, and Bone Density in Psoriatic Arthritis and Rheumatoid Arthritis Patients Followed in a Large U.S. Disease Registry. Journal of Rheumatology, 2010, 37, 2566-2572.	2.0	31
126	Functional impairment measurement in psoriatic arthritis: Importance and challenges. Seminars in Arthritis and Rheumatism, 2018, 48, 436-448.	3.4	29

#	ARTICLE	IF	CITATIONS
127	Assessing structural damage progression in psoriatic arthritis and its role as an outcome in research. Arthritis Research and Therapy, 2020, 22, 18.	3.5	29
128	Patient Support Program Increased Medication Adherence with Lower Total Health Care Costs Despite Increased Drug Spending. Journal of Managed Care & Specialty Pharmacy, 2019, 25, 770-779.	0.9	28
129	Ustekinumab Fails to Show Efficacy in a Phase <scp>III</scp> Axial Spondyloarthritis Program: The Importance of Negative Results. Arthritis and Rheumatology, 2019, 71, 179-181.	5.6	28
130	Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1). Rheumatology, 2018, 57, 1777-1788.	1.9	27
131	Development of Criteria to Distinguish Inflammatory from Noninflammatory Arthritis, Enthesitis, Dactylitis, and Spondylitis: A Report from the GRAPPA 2013 Annual Meeting. Journal of Rheumatology, 2014, 41, 1249-1251.	2.0	24
132	Report of the GRAPPA-OMERACT Psoriatic Arthritis Working Group from the GRAPPA 2015 Annual Meeting. Journal of Rheumatology, 2016, 43, 965-969.	2.0	24
133	Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial. RMD Open, 2017, 3, e000415.	3.8	24
134	Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2Âyears: results from the FUTURE 2 study. Arthritis Research and Therapy, 2018, 20, 113.	3.5	24
135	Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 study. Lancet Rheumatology, The, 2020, 2, e227-e235.	3.9	23
136	Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: results from a Delphi consensus study. Nature Reviews Rheumatology, 2021, 17, 238-243.	8.0	23
137	Psoriatic arthritis update. Bulletin of the NYU Hospital for Joint Diseases, 2006, 64, 25-31.	0.7	23
138	Is methotrexate effective in psoriatic arthritis?. Nature Reviews Rheumatology, 2012, 8, 251-252.	8.0	22
139	A psychometric analysis of outcome measures in peripheral spondyloarthritis. Annals of the Rheumatic Diseases, 2016, 75, 1302-1307.	0.9	22
140	Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 study. Seminars in Arthritis and Rheumatism, 2020, 50, 709-718.	3.4	22
141	Enthesitis in psoriatic arthritis (Part 3): clinical assessment and management. Rheumatology, 2020, 59, i21-i28.	1.9	22
142	Characterization of Patients With Axial Spondyloarthritis by Enthesitis Presence: Data from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. ACR Open Rheumatology, 2020, 2, 449-456.	2.1	22
143	Understanding the association between skin involvement and joint activity in patients with psoriatic arthritis: experience from the Corrona Registry. RMD Open, 2019, 5, e000867.	3.8	21
144	Patientâ€™s experience of psoriatic arthritis: a conceptual model based on qualitative interviews. RMD Open, 2020, 6, e001321.	3.8	21

#	ARTICLE	IF	CITATIONS
145	Impact of Adalimumab on Symptoms of Psoriatic Arthritis in Patients with Moderate to Severe Psoriasis: A Pooled Analysis of Randomized Clinical Trials. <i>Dermatology</i> , 2010, 220, 1-7.	2.1	20
146	Is Chronic Pain a Disease in Its Own Right? Discussions from a Pre-OMERACT 2014 Workshop on Chronic Pain. <i>Journal of Rheumatology</i> , 2015, 42, 1947-1953.	2.0	20
147	Clinical and Patient-reported Outcomes in Patients with Psoriatic Arthritis (PsA) by Body Surface Area Affected by Psoriasis: Results from the Corrona PsA/Spondyloarthritis Registry. <i>Journal of Rheumatology</i> , 2017, 44, 1151-1158.	2.0	20
148	Classification and Outcome Measures for Psoriatic Arthritis. <i>Frontiers in Medicine</i> , 2018, 5, 246.	2.6	20
149	Pooled Safety Results Through 1 Year of 2 Phase III Trials of Guselkumab in Patients With Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2021, 48, 1815-1823.	2.0	20
150	A short history of biological therapy for psoriatic arthritis. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S104-8.	0.8	20
151	Assessing Physical Activity and Sleep in Axial Spondyloarthritis: Measuring the Gap. <i>Rheumatology and Therapy</i> , 2019, 6, 487-501.	2.3	19
152	Measurement properties of the minimal disease activity criteria for psoriatic arthritis. <i>RMD Open</i> , 2019, 5, e001002.	3.8	19
153	Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study. <i>RMD Open</i> , 2020, 6, e001217.	3.8	19
154	Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study. <i>Lancet Rheumatology</i> , The, 2021, 3, e270-e283.	3.9	19
155	The International Dermatology Outcome Measures Initiative as Applied to Psoriatic Disease Outcomes: A Report from the GRAPPA 2013 Meeting. <i>Journal of Rheumatology</i> , 2014, 41, 1227-1229.	2.0	18
156	The OMERACT MRI in Arthritis Working Group "Update on Status and Future Research Priorities. <i>Journal of Rheumatology</i> , 2015, 42, 2470-2472.	2.0	18
157	Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. <i>RMD Open</i> , 2020, 6, e001042.	3.8	18
158	Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies. <i>Rheumatology</i> , 2021, 60, 5337-5350.	1.9	18
159	Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study. <i>RMD Open</i> , 2021, 7, e001600.	3.8	18
160	Instrument selection for the ASAS core outcome set for axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, 763-772.	0.9	18
161	Design and rationale of the Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA). <i>RMD Open</i> , 2018, 4, e000606.	3.8	17
162	Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies. <i>Arthritis Research and Therapy</i> , 2019, 21, 266.	3.5	17

#	ARTICLE	IF	CITATIONS
163	Is reduction or discontinuation of therapy an acceptable possibility in psoriatic arthritis?. Clinical and Experimental Rheumatology, 2013, 31, S59-62.	0.8	17
164	Evaluation of the effect of baseline MRI sacroiliitis and C reactive protein status on etanercept treatment response in non-radiographic axial spondyloarthritis: a post hoc analysis of the EMBARK study. Annals of the Rheumatic Diseases, 2018, 77, 1091-1093.	0.9	16
165	GRAPPA-OMERACT initiative to standardise outcomes in psoriatic arthritis clinical trials and longitudinal observational studies. Annals of the Rheumatic Diseases, 2018, 77, e23-e23.	0.9	16
166	Remission in psoriatic arthritis“where are we now?. Rheumatology, 2018, 57, 1321-1331.	1.9	16
167	Matching-adjusted indirect comparison: secukinumab versus infliximab in biologic-naïve patients with psoriatic arthritis. Journal of Comparative Effectiveness Research, 2019, 8, 497-510.	1.4	15
168	Effect of Multidomain Disease Presentations on Patients With Psoriatic Arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. Journal of Rheumatology, 2021, 48, 698-706.	2.0	15
169	Secukinumab Efficacy in Psoriatic Arthritis. Journal of Clinical Rheumatology, 2021, 27, 239-247.	0.9	14
170	The GRAPPA-OMERACT Psoriatic Arthritis Working Group at the 2018 Annual Meeting: Report and Plan for Completing the Core Outcome Measurement Set. Journal of Rheumatology, 2019, 95, 33-37.	2.0	14
171	Tumor Necrosis Factor Inhibitor Discontinuation in Patients with Ankylosing Spondylitis: An Observational Study From the US-Based Corrona Registry. Rheumatology and Therapy, 2018, 5, 537-550.	2.3	13
172	<p>Participation in an innovative patient support program reduces prescription abandonment for adalimumab-treated patients in a commercial population</p>. Patient Preference and Adherence, 2019, Volume 13, 1545-1556.	1.8	13
173	Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis. Rheumatology, 2021, 60, 1137-1147.	1.9	13
174	IL-23 and axial disease: do they come together?. Rheumatology, 2021, 60, iv28-iv33.	1.9	13
175	Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response“results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis. Arthritis Research and Therapy, 2021, 23, 190.	3.5	13
176	Withdrawing Ixekizumab in Patients With Psoriatic Arthritis Who Achieved Minimal Disease Activity: Results From a Randomized, Double“Blind Withdrawal Study. Arthritis and Rheumatology, 2021, 73, 1663-1672.	5.6	13
177	Comparison of Clinical Manifestations in Rheumatoid Arthritis vs. Spondyloarthritis: A Systematic Literature Review. Rheumatology and Therapy, 2022, 9, 331-378.	2.3	13
178	Changes in Treatment Patterns in Patients with Psoriatic Arthritis Initiating Biologic and Nonbiologic Therapy in a Clinical Registry. Journal of Rheumatology, 2017, 44, 184-192.	2.0	12
179	2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Journal of Psoriasis and Psoriatic Arthritis, 2019, 4, 31-58.	0.7	12
180	Potential Impact of Sex and BMI on Response to Therapy in Psoriatic Arthritis: Post Hoc Analysis of Results From the SEAM-PsA Trial. Journal of Rheumatology, 2022, 49, 885-893.	2.0	12

#	ARTICLE	IF	CITATIONS
181	Pain mechanisms and ultrasonic inflammatory activity as prognostic factors in patients with psoriatic arthritis: protocol for a prospective, exploratory cohort study. <i>BMJ Open</i> , 2016, 6, e010650.	1.9	11
182	Emerging Immunomodulatory Therapies and New Treatment Paradigms for Axial Spondyloarthritis. <i>Current Rheumatology Reports</i> , 2019, 21, 35.	4.7	11
183	Measuring Outcomes in Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2020, 72, 82-109.	3.4	11
184	Measuring Outcomes in Axial Spondyloarthritis. <i>Arthritis Care and Research</i> , 2020, 72, 47-71.	3.4	11
185	Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies. <i>RMD Open</i> , 2022, 8, e002195.	3.8	11
186	Progression of fibromyalgia: results from a 2-year observational fibromyalgia and chronic pain study in the US. <i>Journal of Pain Research</i> , 2016, 9, 325.	2.0	10
187	Physicianâ€™s Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA Study. <i>Journal of Rheumatology</i> , 2018, 45, 1256-1262.	2.0	10
188	Effect of Secukinumab on the Different GRAPPA-OMERACT Core Domains in Psoriatic Arthritis: A Pooled Analysis of 2049 Patients. <i>Journal of Rheumatology</i> , 2020, 47, 854-864.	2.0	10
189	Treatment patterns in rheumatoid arthritis patients newly initiated on biologic and conventional synthetic disease-modifying antirheumatic drug therapy and enrolled in a North American clinical registry. <i>Arthritis Research and Therapy</i> , 2021, 23, 236.	3.5	10
190	Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting. <i>Journal of Rheumatology</i> , 2018, 94, 17-25.	2.0	10
191	Current Treatment for Psoriatic Arthritis and Other Spondyloarthritides. <i>Rheumatic Disease Clinics of North America</i> , 2006, 32, 11-20.	1.9	9
192	Improved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: results from a phase 3 trial. <i>Arthritis Research and Therapy</i> , 2018, 20, 269.	3.5	9
193	Baseline patient characteristics associated with response to biologic therapy in patients with psoriatic arthritis enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. <i>RMD Open</i> , 2018, 4, e000638.	3.8	9
194	Evaluation of Clinical Diagnosis of Axial Psoriatic Arthritis (PsA) or Elevated Patient-reported Spine Pain in CorEvitasâ€™ PsA/Spondyloarthritis Registry. <i>Journal of Rheumatology</i> , 2022, 49, 281-290.	2.0	9
195	Effect of bimekizumab on symptoms and impact of disease in patients with psoriatic arthritis over 3 years: results from BE ACTIVE. <i>Rheumatology</i> , 2023, 62, 617-628.	1.9	9
196	Harmonizing Pain Outcome Measures: Results of the Pre-OMERACT Meeting on Partnerships for Consensus on Patient-important Pain Outcome Domains Between the Cochrane Musculoskeletal Group and OMERACT. <i>Journal of Rheumatology</i> , 2015, 42, 1943-1946.	2.0	8
197	Body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis: a <i>post hoc</i> analysis of a phase III trial. <i>RMD Open</i> , 2019, 5, e000934.	3.8	8
198	Evaluation of Improvement in Skin and Nail Psoriasis in Bioâ€™naïve Patients With Active Psoriatic Arthritis Treated With Golumumab: Results Through Week 52 of the GOâ€™VIBRANT Study. <i>ACR Open Rheumatology</i> , 2020, 2, 640-647.	2.1	8

#	ARTICLE	IF	CITATIONS
199	Updates on Axial Psoriatic Arthritis From the 2020 GRAPPA Annual Meeting. Journal of Rheumatology, 2021, , jrheum.201672.	2.0	8
200	Report of the Skin Research Working Groups From the GRAPPA 2020 Annual Meeting. Journal of Rheumatology, 2021, , jrheum.201668.	2.0	8
201	Infliximab (Remicade) in the treatment of psoriatic arthritis. Therapeutics and Clinical Risk Management, 2006, 2, 389-400.	2.0	8
202	Comparison between adalimumab introduction and methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis (CONTROL): a randomised, open-label, two-part, phase 4 study. Lancet Rheumatology, The, 2022, 4, e262-e273.	3.9	8
203	Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials. RMD Open, 2022, 8, e002049.	3.8	8
204	Current State of Reporting Pain Outcomes in Cochrane Reviews of Chronic Musculoskeletal Pain Conditions and Considerations for an OMERACT Research Agenda. Journal of Rheumatology, 2015, 42, 1934-1942.	2.0	7
205	Evidence for Psoriatic Arthritis Impact of Disease (PsAID12) as Core Instrument to Measure Health-Related Quality of Life in Psoriatic Arthritis: A Systematic Review of Psychometric Properties. Journal of Psoriasis and Psoriatic Arthritis, 2020, 5, 12-22.	0.7	7
206	Establishing core domain sets for Chronic Nonbacterial Osteomyelitis (CNO) and Synovitis, Acne, Pustulosis, Hyperostosis, Osteitis (SAPHO): A report from the OMERACT 2020 special interest group. Seminars in Arthritis and Rheumatism, 2021, 51, 957-961.	3.4	7
207	GRAPPA 2018 Project Report. Journal of Rheumatology, 2019, 95, 54-57.	2.0	7
208	GRAPPA 2019 Project Report. Journal of Rheumatology, 2020, 96, 53-57.	2.0	7
209	Treatmentâ€”Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease Manifestations. Arthritis Care and Research, 2020, 72, 814-821.	3.4	6
210	Clinical trial discrimination of physical function instruments for psoriatic arthritis: A systematic review. Seminars in Arthritis and Rheumatism, 2020, 50, 1158-1181.	3.4	6
211	Psoriasis and Psoriatic Arthritis in the Context of the COVID-19 Pandemic: A Plenary Session From the GRAPPA 2020 Annual Meeting. Journal of Rheumatology, 2021, , jrheum.201671.	2.0	6
212	Secukinumab Efficacy on Psoriatic Arthritis GRAPPA-OMERACT Core Domains in Patients with or Without Prior Tumor Necrosis Factor Inhibitor Use: Pooled Analysis of Four Phase 3 Studies. Rheumatology and Therapy, 2021, 8, 1223-1240.	2.3	6
213	Differentiating nonradiographic axial spondyloarthritis from its mimics: a narrative review. BMC Musculoskeletal Disorders, 2022, 23, 240.	1.9	6
214	Early Real-World Experience of Tofacitinib for Psoriatic Arthritis: Data from a United States Healthcare Claims Database. Advances in Therapy, 2022, 39, 2932-2945.	2.9	6
215	Long-term efficacy and predictors of remission following adalimumab treatment in peripheral spondyloarthritis: 3-year results from ABILITY-2. RMD Open, 2018, 4, e000566.	3.8	5
216	Persistence of tumor necrosis factor inhibitor or conventional synthetic disease-modifying antirheumatic drug monotherapy or combination therapy in psoriatic arthritis in a real-world setting. Rheumatology International, 2019, 39, 1547-1558.	3.0	5

#	ARTICLE	IF	CITATIONS
217	Appraisal of Candidate Instruments for Assessment of the Physical Function Domain in Patients with Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2021, 48, 58-66.	2.0	5
218	Comparative effectiveness of secukinumab and etanercept in biologic-naïve patients with psoriatic arthritis assessed by matching-adjusted indirect comparison. <i>European Journal of Rheumatology</i> , 2019, 6, 113-121.	0.6	5
219	The Benefits and Challenges of Setting Up a Longitudinal Psoriatic Arthritis Database. <i>Journal of Rheumatology</i> , 2018, 94, 26-29.	2.0	5
220	Biopsychosocial Rehabilitation for Inflammatory Arthritis and Osteoarthritis Patients: A Systematic Review and Meta-Analysis of Randomized Trials. <i>Arthritis Care and Research</i> , 2023, 75, 423-436.	3.4	5
221	Variations in the management of fibromyalgia by physician specialty: rheumatology versus primary care. <i>Journal of Pragmatic and Observational Research</i> , 2016, 7, 11.	1.5	4
222	Measuring psoriatic arthritis symptoms: A core domain in psoriasis clinical trials. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 54-61.	1.2	4
223	Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib. <i>RMD Open</i> , 2021, 7, e001609.	3.8	4
224	OMERACT Filter 2.1 instrument selection for physical function domain in psoriatic arthritis: Provisional endorsement for HAQ-DI and SF-36 PF. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1117-1124.	3.4	4
225	Change in psoriatic arthritis outcome measures impacts SF-36 physical and mental component scores differently: an observational cohort study. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkab076.	0.7	4
226	Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets With Apremilast: Phase III Results in DMARD-naïve Patients With Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2022, 49, 694-699.	2.0	4
227	Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results. <i>Clinical Rheumatology</i> , 2022, 41, 3035-3047.	2.2	4
228	Reply. <i>Arthritis and Rheumatology</i> , 2015, 67, 2793-2794.	5.6	3
229	GRAPPA 2015 Research and Education Project Reports. <i>Journal of Rheumatology</i> , 2016, 43, 979-985.	2.0	3
230	Performance and Predictors of Minimal Disease Activity Response in Peripheral Spondyloarthritis Patients Treated With Adalimumab. <i>Arthritis Care and Research</i> , 2020, , .	3.4	3
231	Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial. <i>Arthritis Research and Therapy</i> , 2020, 22, 43.	3.5	3
232	Poor prognostic factors in predicting abatacept response in a phase III randomized controlled trial in psoriatic arthritis. <i>Rheumatology International</i> , 2020, 40, 1021-1028.	3.0	3
233	Suspecting and Diagnosing the Patient with Spondyloarthritis and What to Expect from Therapy. <i>Medical Clinics of North America</i> , 2021, 105, 325-339.	2.5	3
234	Pustular Psoriasis and Associated Musculoskeletal Disorders. <i>Journal of Rheumatology</i> , 2021, , jrheum.201673.	2.0	3

#	ARTICLE	IF	CITATIONS
235	Test-retest Reliability for HAQ-DI and SF-36 PF for the Measurement of Physical Function in Psoriatic Arthritis. Journal of Rheumatology, 2021, 48, 1547-1551.	2.0	3
236	Pain in Axial Spondyloarthritis: More to It Than Just Inflammation. Journal of Rheumatology, 2021, 48, 1632-1634.	2.0	3
237	Domains to Be Considered for the Core Outcome Set of Axial Spondyloarthritis: Results From a 3-round Delphi Survey. Journal of Rheumatology, 2021, 48, 1810-1814.	2.0	3
238	GRAPPA 2017 Project Report. Journal of Rheumatology, 2018, 94, 48-51.	2.0	3
239	The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomised phase 3 trial. Lancet Rheumatology, The, 2022, 4, e208-e219.	3.9	3
240	Effectiveness of 6-month Use of Secukinumab in Patients With Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. Journal of Rheumatology, 2022, 49, 700-706.	2.0	3
241	Correspondence on “No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related “physician-reported spondylitis””. Annals of the Rheumatic Diseases, 2023, 82, e187-e187.	0.9	3
242	Disease Control with Upadacitinib in Patients with Psoriatic Arthritis: A Post Hoc Analysis of the Randomized, Placebo-Controlled SELECT-PsA 1 and 2 Phase 3 Trials. Rheumatology and Therapy, 0, , .	2.3	3
243	Presidential Round Table: A Report from the GRAPPA Annual Meeting. Journal of Rheumatology, 2016, 43, 986-989.	2.0	2
244	GRAPPA 2016 Project Report. Journal of Rheumatology, 2017, 44, 706-710.	2.0	2
245	Tofacitinib for Psoriatic Arthritis. New England Journal of Medicine, 2018, 378, 775-776.	27.0	2
246	Reply. Arthritis and Rheumatology, 2020, 72, 1229-1230.	5.6	2
247	Relation Between Fatigue and ACR Response in Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitor Therapy: A Population-based Cohort Study. Journal of Rheumatology, 2021, 48, 829-835.	2.0	2
248	Instruments Measuring Physical Function for Psoriatic Arthritis Endorsed at GRAPPA 2020 Annual Meeting: Updates of the GRAPPA-OMERACT Working Group. Journal of Rheumatology, 2021, , jrheum.201679.	2.0	2
249	Measurement properties of radiographic outcome measures in Psoriatic Arthritis: A systematic review from the GRAPPA-OMERACT initiative. Seminars in Arthritis and Rheumatism, 2021, 51, 367-386.	3.4	2
250	Treatment Responses in Patients With Psoriatic Arthritis Axial Disease According to Human Leukocyte <sc>Antigen-B27</sc> Status: An Analysis From the <sc>CorEvitas</sc> Psoriatic Arthritis/Spondyloarthritis Registry. ACR Open Rheumatology, 2022, 4, 447-456.	2.1	2
251	COVID-19 Update for the GRAPPA 2021 Annual Meeting: Focus on COVID-19 Vaccination. Journal of Rheumatology, 2022, , jrheum.211319.	2.0	2
252	077. “PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS ACHIEVING MINIMAL DISEASE ACTIVITY WITH SECUKINUMAB TREATMENT DEMONSTRATE SUSTAINED IMPROVEMENT OF FUNCTION AND QUALITY OF LIFE. Rheumatology, 2017, 56, .	1.9	1

#	ARTICLE	IF	CITATIONS
253	Current and Emerging Treatments for Psoriatic Arthritis. , 2018, , 175-185.		1
254	Preface to the psoriatic arthritis supplement. Rheumatology, 2020, 59, i1-i3.	1.9	1
255	Patient-reported outcomes data in patients with psoriatic arthritis from a randomised trial of etanercept and methotrexate as monotherapy or in combination. RMD Open, 2021, 7, e001484.	3.8	1
256	Dr. Mease et al reply. Journal of Rheumatology, 2021, 48, jrheum.210750.	2.0	1
257	Plain Radiographic Instruments for Structural Damage in Peripheral Joints in Psoriatic Arthritis: A Report From the GRAPPA-OMERACT Working Group. Journal of Rheumatology, 2022, , jrheum.211322.	2.0	1
258	Articular and Extra-Articular Benefits in ACR20 Non-responders at Week 104 Treated With Apremilast: Pooled Analysis of Three Randomized Controlled Trials. Rheumatology and Therapy, 2021, 8, 1677-1691.	2.3	1
259	Psoriatic Arthritis: Current Treatment Options. Psoriasis Forum, 2003, 9a, 4-6.	0.1	0
260	Adalimumab in Psoriatic Arthritis. Drugs, 2006, 66, 1497-1499.	10.9	0
261	AB0765â€¦THE IMPACT OF PSORIASIS SEVERITY ON OUTCOMES AMONG PSORIATIC ARTHRITIS PATIENTS RECEIVING ADALIMUMAB. , 2019, , .		0
262	AB0763â€¦SAFETY OF ABATACEPT TREATMENT OVER 2 YEARS IN A PHASE III ACTIVE PSORIATIC ARTHRITIS RANDOMIZED TRIAL (ASTRAEA). , 2019, , .		0
263	P261â€¦Continuing versus withdrawing ixekizumab in patients with PsA who achieved sustained minimal disease activity: results from the SPIRIT-P3 study. Rheumatology, 2020, 59, .	1.9	0
264	New treatments for PsA meet targeted therapy goals. Nature Reviews Rheumatology, 2021, 17, 77-78.	8.0	0
265	GRAPPA 2020 Update From the Education Committee. Journal of Rheumatology, 2021, , jrheum.201678.	2.0	0
266	Basic Science Session 1. Biomarkers for Psoriatic Arthritis Treatment Response and Joint Damage Progression: An Update on 2 Industry-GRAPPA Projects. Journal of Rheumatology, 2022, , jrheum.211320.	2.0	0
267	Challenges in the Diagnosis and Assessment of Psoriatic Arthritis. Journal of Rheumatology, 2022, , jrheum.211337.	2.0	0
268	2021 GRAPPA Meet the Experts Session: A Summary of Presentations.. Journal of Rheumatology, 2022, , .	2.0	0